Cargando…
Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis
OBJECTIVE: Little information is available about the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for patients with secondary myelofibrosis from essential thrombocythemia (ET) and polycythemia vera (PV). A nationwide retrospective study of the outcome of HSCT for post-ET and...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492130/ https://www.ncbi.nlm.nih.gov/pubmed/32801269 http://dx.doi.org/10.2169/internalmedicine.4375-19 |
_version_ | 1783582325181775872 |
---|---|
author | Murata, Makoto Suzuki, Ritsuro Nishida, Tetsuya Shirane, Shuichi Shimazu, Yutaka Minami, Yosuke Mori, Takehiko Doki, Noriko Kanda, Yoshinobu Uchida, Naoyuki Tanaka, Masatsugu Ishikawa, Jun Togitani, Kazuto Fukuda, Takahiro Ichinohe, Tatsuo Atsuta, Yoshiko Nagamura-Inoue, Tokiko Kiyoi, Hitoshi |
author_facet | Murata, Makoto Suzuki, Ritsuro Nishida, Tetsuya Shirane, Shuichi Shimazu, Yutaka Minami, Yosuke Mori, Takehiko Doki, Noriko Kanda, Yoshinobu Uchida, Naoyuki Tanaka, Masatsugu Ishikawa, Jun Togitani, Kazuto Fukuda, Takahiro Ichinohe, Tatsuo Atsuta, Yoshiko Nagamura-Inoue, Tokiko Kiyoi, Hitoshi |
author_sort | Murata, Makoto |
collection | PubMed |
description | OBJECTIVE: Little information is available about the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for patients with secondary myelofibrosis from essential thrombocythemia (ET) and polycythemia vera (PV). A nationwide retrospective study of the outcome of HSCT for post-ET and post-PV myelofibrosis was conducted in Japan. PATIENTS AND METHODS: Clinical data for patients with post-ET (n=29) and post-PV (n=9) myelofibrosis who had received first allogeneic HSCT were extracted from the Transplant Registry Unified Management Program, which is a registry of the outcomes of HSCT in Japan. RESULTS: Five patients died without neutrophil recovery within 60 days after transplantation. The incidence of neutrophil recovery was significantly lower in umbilical cord blood (UCB) transplantation than in related donor transplantation (40% vs. 92%, p=0.010). The 1-year non-relapse mortality for post-ET and post-PV myelofibrosis was 35% and 27%, respectively (p=0.972). No patient or transplantation characteristics were associated with non-relapse mortality. The 4-year overall survival for post-ET and post-PV myelofibrosis was 46% and 65%, respectively (p=0.362). A univariate analysis identified UCB transplantation (vs. related donor, p=0.017) and ≥10 times red blood cell transfusions before transplantation (vs. <10 times, p=0.037) as predictive of a lower overall survival. CONCLUSION: Allogeneic HSCT provides a long-term survival for at least some patients with post-ET and post-PV myelofibrosis. Further studies with more patients are required to determine the best alternative donor. |
format | Online Article Text |
id | pubmed-7492130 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Japanese Society of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-74921302020-09-23 Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis Murata, Makoto Suzuki, Ritsuro Nishida, Tetsuya Shirane, Shuichi Shimazu, Yutaka Minami, Yosuke Mori, Takehiko Doki, Noriko Kanda, Yoshinobu Uchida, Naoyuki Tanaka, Masatsugu Ishikawa, Jun Togitani, Kazuto Fukuda, Takahiro Ichinohe, Tatsuo Atsuta, Yoshiko Nagamura-Inoue, Tokiko Kiyoi, Hitoshi Intern Med Original Article OBJECTIVE: Little information is available about the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for patients with secondary myelofibrosis from essential thrombocythemia (ET) and polycythemia vera (PV). A nationwide retrospective study of the outcome of HSCT for post-ET and post-PV myelofibrosis was conducted in Japan. PATIENTS AND METHODS: Clinical data for patients with post-ET (n=29) and post-PV (n=9) myelofibrosis who had received first allogeneic HSCT were extracted from the Transplant Registry Unified Management Program, which is a registry of the outcomes of HSCT in Japan. RESULTS: Five patients died without neutrophil recovery within 60 days after transplantation. The incidence of neutrophil recovery was significantly lower in umbilical cord blood (UCB) transplantation than in related donor transplantation (40% vs. 92%, p=0.010). The 1-year non-relapse mortality for post-ET and post-PV myelofibrosis was 35% and 27%, respectively (p=0.972). No patient or transplantation characteristics were associated with non-relapse mortality. The 4-year overall survival for post-ET and post-PV myelofibrosis was 46% and 65%, respectively (p=0.362). A univariate analysis identified UCB transplantation (vs. related donor, p=0.017) and ≥10 times red blood cell transfusions before transplantation (vs. <10 times, p=0.037) as predictive of a lower overall survival. CONCLUSION: Allogeneic HSCT provides a long-term survival for at least some patients with post-ET and post-PV myelofibrosis. Further studies with more patients are required to determine the best alternative donor. The Japanese Society of Internal Medicine 2020-08-15 2020-08-15 /pmc/articles/PMC7492130/ /pubmed/32801269 http://dx.doi.org/10.2169/internalmedicine.4375-19 Text en Copyright © 2020 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Murata, Makoto Suzuki, Ritsuro Nishida, Tetsuya Shirane, Shuichi Shimazu, Yutaka Minami, Yosuke Mori, Takehiko Doki, Noriko Kanda, Yoshinobu Uchida, Naoyuki Tanaka, Masatsugu Ishikawa, Jun Togitani, Kazuto Fukuda, Takahiro Ichinohe, Tatsuo Atsuta, Yoshiko Nagamura-Inoue, Tokiko Kiyoi, Hitoshi Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis |
title | Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis |
title_full | Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis |
title_fullStr | Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis |
title_full_unstemmed | Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis |
title_short | Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis |
title_sort | allogeneic hematopoietic stem cell transplantation for post-essential thrombocythemia and post-polycythemia vera myelofibrosis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492130/ https://www.ncbi.nlm.nih.gov/pubmed/32801269 http://dx.doi.org/10.2169/internalmedicine.4375-19 |
work_keys_str_mv | AT muratamakoto allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis AT suzukiritsuro allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis AT nishidatetsuya allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis AT shiraneshuichi allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis AT shimazuyutaka allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis AT minamiyosuke allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis AT moritakehiko allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis AT dokinoriko allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis AT kandayoshinobu allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis AT uchidanaoyuki allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis AT tanakamasatsugu allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis AT ishikawajun allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis AT togitanikazuto allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis AT fukudatakahiro allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis AT ichinohetatsuo allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis AT atsutayoshiko allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis AT nagamurainouetokiko allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis AT kiyoihitoshi allogeneichematopoieticstemcelltransplantationforpostessentialthrombocythemiaandpostpolycythemiaveramyelofibrosis |